Actively Recruiting
Comparison of the Effects of Prophylactic Apixaban on Thrombin Generation in Patients With New Multiple Myeloma and Those Undergoing Total Knee Replacement Surgery
Led by Centre Hospitalier Universitaire de Saint Etienne · Updated on 2025-09-25
32
Participants Needed
1
Research Sites
26 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating how Apixaban, a medication recommended to prevent blood clots, affects blood clotting in patients with newly diagnosed multiple myeloma (MM) compared to patients undergoing total knee replacement surgery who also receive blood clot prevention. This study aims to understand if differences in how the drug is processed in the body impact its ability to reduce blood clotting in these two groups. The findings may help improve blood clot prevention in MM patients. The study includes two groups: one with patients newly diagnosed with multiple myeloma who need Apixaban to prevent blood clots, and another with patients having surgery for total knee replacement who also require Apixaban. Blood samples will be taken from both groups to measure the medication's concentration and its effects on blood clotting over a 12-hour period after treatment. Participants will have blood samples collected to analyze how Apixaban influences thrombin generation, a key factor in blood clotting, measured 2 hours after treatment and monitored over 12 hours. The study will track Apixaban levels and several clotting parameters, including lag time, time to peak, and thrombin peak. This non-randomized, single-blind trial will last until September 2027, and participants' safety and clotting responses will be carefully observed throughout.
CONDITIONS
Brief Title
Comparison of the Effects of Apixaban on Thrombin Generation in Patients With de Novo Multiple Myeloma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Signed informed consent
- Covered by a social security scheme
- Patients with a diagnosis of new multiple myeloma needing Apixaban for blood clot prevention
- Patients scheduled for total knee replacement surgery needing Apixaban for blood clot prevention
You will not qualify if you...
- Receiving curative doses of anticoagulation treatment
- Contraindication to Apixaban
- Pregnant or breastfeeding women
- Refusal to sign consent
- Patients under legal protection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 12 hours following Apixaban treatment
Participants receive treatment with Apixaban and undergo blood sampling to assess thrombin generation and Apixaban pharmacodynamics.
1 treatment period with blood sampling visits during 12 hours
Trial Site Locations
Total: 1 location
1
CHU de Saint-Etienne
Saint-Etienne, France, 42055
Actively Recruiting
Research Team
E
Emilie CHALAYER, MD
F
Florence RANCON
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here